Welcome to our dedicated page for Silence Therapeutics Plc news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc stock.
Silence Therapeutics plc (Nasdaq: SLN) generates a steady flow of news as a global clinical-stage biotechnology company developing siRNA (short interfering RNA) therapies. Its updates focus on the progress of programs built on its proprietary mRNAi GOLD™ platform, which is designed to create precision engineered siRNAs that target and silence disease-associated genes in the liver.
Investors following SLN news can expect detailed coverage of clinical trial milestones, particularly for divesiran, the company’s first-in-class siRNA candidate for polycythemia vera (PV). Recent announcements describe additional Phase 1 data presented at major hematology meetings, durable hematocrit control and reduced need for phlebotomies in PV patients, and the completion of enrollment in the global, randomized SANRECO Phase 2 study.
Silence also issues news on its broader pipeline and strategy, including updates on zerlasiran for cardiovascular disease, extra-hepatic siRNA targeting work, and its collaboration program SLN312 licensed to AstraZeneca. Financial result press releases provide context on research and development spending, cash and investment balances, and the company’s stated cash runway expectations, alongside commentary on operational priorities.
Corporate governance and leadership developments feature in SLN news as well, such as changes to the Board of Directors, executive transitions and outcomes of shareholder votes at the annual general meeting. Conference participation announcements highlight company presentations at healthcare and investor events, where management discusses the siRNA platform, clinical data and pipeline priorities.
By monitoring this news page, readers can review a chronological record of Silence Therapeutics’ clinical, financial and corporate disclosures related to SLN, with an emphasis on the evolution of its siRNA programs in cardiovascular disease, hematology and rare diseases.
Silence Therapeutics (Nasdaq: SLN) has secured a $2 million payment from Hansoh Pharmaceutical following the achievement of a research milestone in their collaboration. This partnership, initiated in October 2021, focuses on developing siRNAs using Silence's mRNAi GOLD™ platform. Hansoh has already paid Silence $16 million upfront, with potential milestones totaling up to $1.3 billion. Silence holds exclusive rights to two targets globally, except in China, while Hansoh has options in the Greater China region. This latest payment marks the fourth research milestone reached under this agreement.
Silence Therapeutics (Nasdaq: SLN) announced positive topline 48-week data from its ALPACAR-360 Phase 2 study of zerlasiran, a siRNA targeting elevated lipoprotein(a), a key genetic risk factor for cardiovascular disease. The study included 178 subjects with baseline Lp(a) levels of 125 nmol/L or higher, administered doses of 300 mg and 450 mg subcutaneously. Results showed a 90% or greater median reduction in Lp(a) from baseline compared to placebo. Zerlasiran was well tolerated with no serious safety concerns. The company plans to advance to Phase 3 trials.
Silence Therapeutics (Nasdaq: SLN) announced its participation in the Jefferies Global Healthcare Conference on June 6th at 2:30 p.m. ET. The company, known for its innovative biotechnology solutions aimed at silencing diseases through precision-engineered medicines, will provide a presentation accessible via live webcast on the company's investor section. An archived replay will also be available after the event.
Silence Therapeutics (NASDAQ: SLN) disclosed its Q1 2024 financials and recent advancements. The firm reported a cash position of £152.8 million ($192.8 million), up from £62.9 million ($77.8 million) a year prior. Collaboration revenue rose by £1.0 million to £12.4 million, largely due to a £9.2 million milestone payment from AstraZeneca. R&D expenses decreased by £3.4 million to £9.2 million, and G&A expenses dropped by £1.3 million to £5.2 million. This resulted in a net loss of £1.9 million, a significant improvement from the £10.2 million loss last year.
Key pipeline updates included positive 36-week data from the phase 2 ALPACAR-360 study of zerlasiran for cardiovascular disease, with primary endpoints met and no new safety concerns. Additionally, promising phase 1 data for divesiran in polycythemia vera (PV) patients were reported. Collaboratively, Silence achieved a $10 million milestone from AstraZeneca after initiating a phase 1 trial.
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The Company focuses on precision engineered medicines to silence diseases, aiming to transform people's lives. The event will take place on May 20th, 2:30 p.m. ET, with a live webcast accessible on the Silence website and an archived replay available post-conference.
Silence Therapeutics plc announced the retirement of Alistair Gray, an independent member of the Board of Directors since 2015, effective May 1, 2024. Alistair Gray made significant contributions during his tenure, marking a period of growth and transformation for the company under the leadership of Iain Ross and Craig Tooman. The Company transitioned into a global player focusing on RNA interference, developed a pipeline of innovative product candidates, and secured big pharma partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.